Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Oct;50 Suppl 40(0 40):S74-9.
doi: 10.1002/ppul.23244.

Tackling the increasing complexity of CF care

Gregory S Sawicki  1 , Christopher H Goss  2
Affiliations
Review

Tackling the increasing complexity of CF care

Gregory S Sawicki et al. Pediatr Pulmonol. 2015 Oct.

Abstract

Health outcomes for individuals with cystic fibrosis (CF) have dramatically improved in parallel with better organization of clinical care systems, evolution of novel therapeutics, and improvements in diagnosis and screening for CF and CF-related complications. In parallel with these advances has come an increasing complexity and burden of care, leading to challenges with adherence to treatment regimens. As novel therapeutics continue to be developed and introduced to the CF care regimen, there are clear opportunities to refine and personalize care. This can be done by adding comparative effectiveness research to the CF clinical research paradigm and integrating novel technologies in drug delivery and remote monitoring that can facilitate adherence but also reduce the burden of treatment while maintaining efficacy. This review highlights both the challenges of the increasingly complex treatment regimens in CF and the opportunities to advance care by addressing adherence, implementation science, comparative effectiveness, and integration of novel technologies in CF care.

Keywords: adherence; comparative effectiveness research; implementation research; treatment burden; treatment complexity.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. MacKenzie T, Gifford AH, Sabadosa KA, Quinton HB, Knapp EA, Goss CH, Marshall BC. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry. Ann Intern Med. 2014;161(4):233–241. - PMC - PubMed
    1. Cystic Fibrosis Foundation. Patient Registry Annual Data Report. 2013 http://www.cff.org/UploadedFiles/research/ClinicalResearch/PatientRegist....
    1. Burgel PR, Bellis G, Olesen HV, Viviani L, Zolin A, Blasi F, Elborn JS Europe EETFoTPoCfAwCFi. Future trends in cystic fibrosis demography in 34 European countries. Eur Respir J. 2015 (in press) - PubMed
    1. Flume PA, O’Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ, Jr, Willey-Courand DB, Bujan J, Finder J, Lester M, Quittell L, Rosenblatt R, Vender RL, Hazle L, Sabadosa K, Marshall B Cystic Fibrosis Foundation PTC. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007;176(10):957–969. - PubMed
    1. Flume PA, Robinson KA, O’Sullivan BP, Finder JD, Vender RL, Willey-Courand DB, White TB, Marshall BC Clinical Practice Guidelines for Pulmonary Therapies C. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care. 2009;54(4):522–537. - PubMed

Publication types

MeSH terms

Substances